Cancer Drug Coverage Parity Act of 2013

HR 1801, Cancer Drug Coverage Parity Act/S 1879 Cancer Treatment Parity Act HR 2477 Planning Actively for Cancer Treatment Act HR 2827 Part D Beneficiary Appeals Fairness Act HR 543 Blue Water Navy Vietnam Veterans Act HR 1491 Blue Water Navy Ship Accountability Act S 2844/HR 5503 James Zadroga 9/11 Health and Compensation Reauthorization Act

Client expense: $35,820 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5214 Requires the Secretary of Health and Human Services (HHS) to consult with clinical experts and make recommendations for the use of clinical data registries to improve patient care. S 1879/HR 1801 Cancer Treatment Parity Act of 2013. HR 3033 The SOFTWARE Act.

Client expense: $10,098 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)

Client expense: $320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)

Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).

Client expense: $440,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

21st Century Cures; HR 460, Patients' Access to Treatments Act; PPACA Marketplace Plan Network Adequacy Rules; HR 1801, Cancer Drug Coverage Parity Act; S 1879, Cancer Treatment Parity Act

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of Health Reform Legislation/Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage Cancer Drug Coverage Parity Act (H.R. 1801) Cancer Treatment Parity Act (S. 1879) Patients' Access to Treatments Act (H.R. 460)

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

HR 1801, Cancer Drug Coverage Parity Act/S 1879 Cancer Treatment Parity Act HR 2477 Planning Actively for Cancer Treatment Act HR 2827 Part D Beneficiary Appeals Fairness Act HR 543 Blue Water Navy Vietnam Veterans Act HR 1491 Blue Water Navy Ship Accountability Act S 2844/HR 5503 James Zadroga 9/11 Health and Compensation Reauthorization Act

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues pertaining to quality of care for blood cancers [Patients Access to Treatment Act, H.R. 460 - all provisions; Cancer Drug Coverage Parity Act, H.R. 1801 - all provisions; Kids First Research Act, H.R. 2019 - all provisions; Medicare exceptions process within prescription drug plans, H.R. 2827 - all provisions]

Client expense: Not reported · Firm income: $50,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 1801, Cancer Drug Coverage Parity Act/S 1879 Cancer Treatment Parity Act HR 2477 Planning Actively for Cancer Treatment Act HR 2827 Part D Beneficiary Appeals Fairness Act HR 543 Blue Water Navy Vietnam Veterans Act HR 1491 Blue Water Navy Ship Accountability Act S 2844/HR 5503 James Zaroga 9/11 Health and Compensation Reauthorization Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1801, Cancer Drug Coverage Parity Act/ S 1879 Cancer Treatment Parity Act HR 2477, Planning Actively for Cancer Treatment Act HR 2827, Part D Beneficiary Appeals Fairness Act HR 543, Blue Water Navy Vietnam Veterans Act HR 1491, Blue Water Navy Ship Accountability Act S 2844/HR 5503, James Zadroga 9/11 Health and Compensation Reauthorization Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 460, Patient Access to Treatment Act; HR 1801 Cancer Drug Coverage Parity Act/S. 1989 Cancer Treatment Parity Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

Cancer Drug Coverage Parity Act (H.R. 1801); Cancer Treatment parity Act of 2013 (S. 1879); and Patients Access to Treatment Act (H.R. 460).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).

Client expense: $400,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues pertaining to quality of care for blood cancers [Patients Access to Treatment Act, H.R. 460 - all provisions; Cancer Drug Coverage Parity Act, H.R. 1801 - all provisions; Kids First Research Act, H.R. 2019 - all provisions; Medicare exceptions process within prescription drug plans, H.R. 2827 - all provisions]

Client expense: Not reported · Firm income: $50,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

Issues pertaining to access to quality care for blood cancer patients [the 21st Century Cures Initiative; HR 460, the Patients Access to Treatments Act--all provisions; HR 1801, the Cancer Drug Coverage Parity Act--all provisions; PL 111-148, the Patient Protection and Affordable Care Act--provisions specific to network adequacy, anti-discrimination, and transparency]

Client expense: $56,055 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5214 Requires the Secretary of Health and Human Services (HHS) to consult with clinical experts and make recommendations for the use of clinical data registries to improve patient care. S 1879/HR 1801 Cancer Treatment Parity Act of 2013. HR 3033 The SOFTWARE Act.

Client expense: $36,316 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Implementation of Health Reform Legislation/Patient Protection and Affordable Care Act (P.L. 111-148); Hematology and Oncology Drug Research and Approval Issues; Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144); Clinical Trials Regulations and Coverage; Cancer Drug Coverage Parity Act (H.R. 1801); Cancer Treatment Parity Act (S. 1879); Patients' Access to Treatments Act (H.R. 460)

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives

Client expense: $498,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)

Issues relating to prescription drugs in health care bills; Issues related to coding of products; orphan drug and rare disease bill; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act of 2013 (H.R. 3116); Veterans access legislation (H.R. 3230/H.R. 4810); The America Invents Act; H.R. 5657, the FAST Generics Act of 2014.

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Cancer Drug Coverage Act (H.R. 1801); Cancer Treatment Parity Act of 2013 (S. 1879); and Patients Access to Treatment Act (H.R. 460).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1801, Cancer Drug Coverage Parity Act/ S 1879 Cancer Treatment Parity Act HR 2477, Planning Actively for Cancer Treatment Act HR 2827, Part D Beneficiary Appeals Fairness Act HR 543, Blue Water Navy Vietnam Veterans Act HR 1491, Blue Water Navy Ship Accountability Act S 2844/HR 5503, James Zadroga 9/11 Health and Compensation Reauthorization Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 460, Patient Access to Treatment Act; HR 1801 Cancer Drug Coverage Parity Act/S. 1879 Cancer Treatment Parity Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

HR 1801, Cancer Drug Coverage Parity Act/ S 1879 Cancer Treatment Parity Act HR 2477, Planning Actively for Cancer Treatment Act HR 2827, Part D Beneficiary Appeals Fairness Act HR 543, Blue Water Navy Vietnam Veterans Act HR 1491, Blue Water Navy Ship Accountability Act H.R. 5503, James Zadroga 9/11 Health and Compensation Reauthorization Act

Client expense: $63,500 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to prescription drugs in health care bills; orphan drug and rare disease bills; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (HR 1801); Patients Access to Treatment Act of 2013 (HR 460); MODDERN Cures Act of 2013 (H.R.3116); Veterans access legislation (H.R. 3230/H.R.4810).

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879). Issues related to the Veterans Access to Care Act (H.R. 4810, S. 2450).

Client expense: $470,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of Health Reform Legislation/Patient Protection and Affordable Care Act (P.L. 111-148); Hematology and Oncology Drug Research and Approval Issues; Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144); Clinical Trials Regulations and Coverage; Cancer Drug Coverage Parity Act (H.R. 1801); Cancer Treatment Parity Act (S. 1879); Patients' Access to Treatments Act (H.R. 460)

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Issues pertaining to quality of care for blood cancers [Patients Access to Treatment Act, H.R. 460 - all provisions; Cancer Drug Coverage Parity Act, H.R. 1801 - all provisions; Kids First Research Act, H.R. 2019 - all provisions; Medicare exceptions process within prescription drug plans, H.R. 2827 - all provisions]

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Cancer Drug Coverage Parity Act (H.R. 1801); Cancer Treatment Parity Act of 2013 (S. 1879); Patients Access to Treatment Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES

HR 1801 Cancer Drug Coverage Parity Act / S 1879 Cancer Treatment Parity Act HR 2477 Planning Actively for Cancer Act HR 2827 Part D Beneficiary Appeals Fairness Act HR 543 Blue Water Navy Vietnam Veterans Act HR 1491 Blue Water Navy Ship Accountability Act

Client expense: $53,500 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1801, Cancer Drug Coverage Parity Act/ S 1879 Cancer Treatment Parity Act HR 2477, Planning Actively for Cancer Treatment Act HR 2827, Part D Beneficiary Appeals Fairness Act HR 543, Blue Water Navy Vietnam Veterans Act HR 1491, Blue Water Navy Ship Accountability Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 460 Patient Access to Treatment Act; HR 1801 Cancer Drug Coverage Parity Act/S 1879 Cancer Treatment Parity Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).

Client expense: $500,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues pertaining to access to quality care for blood cancer patients [HR 460, the Patients Access to Treatments Act - all provisions]; [HR 1801, the Cancer Drug Coverage Parity Act - all provisions]; [S 1365/HR 2827, The Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care - provisions specific to network adequacy and cost sharing]; [S. 2115, the American CURES Act - all provisions]; Energy & Commerce committee proposal re: FDA reform

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

-oral oncology parity (H.R. 1801) -340(b) organization and ongoing implementation -Medicare Parts B&D -implementation of Affordable Care Act-speciality tiers related to pharmaceuticals -H.R. 3091 (MODDERN Cures Act)

Client expense: $510,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

Issues pertaining to quality of care for blood cancers [Patients Access to Treatment Act, H.R. 460 - all provisions; Cancer Drug Coverage Parity Act, H.R. 1801 - all provisions; Kids First Research Act, H.R. 2019 - all provisions; Medicare exceptions process within prescription drug plans, H.R. 2827 - all provisions]

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to the implementation of the Affordable Care Act; issues relating to the implementation of the Generating Antibiotic Incentives Now (GAIN) Act; H.R. 4302, Protecting Access to Medicare Act; H.R. 1801, Cancer Drug Coverage Parity Act; issues relating to the 2014 Hospital Outpatient Prospective Payment System; H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2014

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Cancer Drug Coverage Parity Act (H.R. 1801); Cancer Treatment Parity Act of 2013 (S. 1879); Patients Access to Treatment Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Cancer Drug Coverage Parity Act, H.R.1801/S.1879 Cancer Treatment Parity Act

Client expense: $49,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1801, Cancer Drug Coverage Parity Act/S. 1879 Cancer Treatment Parity Act H.R. 2477, Planning Actively for Cancer Treatments Act H.R. 2827, Part D Beneficiary Appeals Fairness Act H.R. 543, Blue Water Navy Vietnam Veterans Act H.R. 1491, Blue Water Navy Ship Accountability Act

Client expense: $49,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of Health Reform Legislation/Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and Oncology Drug Research and Approval Issues Implimentation of The Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage; Cancer Drug Coverage Parity Act (H.R. 1801); Cancer Treatment Parity Act (S. 1879)

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

HR 1801, Cancer Drug Coverage Parity Act/ S. 1879 Cancer Treatment Parity Act HR 2477, Planning Actively for Cancer Treatment Act HR 2827, Part D Beneficiary Appeals Fairness Act HR 543 Blue Water Navy Vietnam Veterans ActHR 1491, Blue Water Navy Ship Accountability Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Cancer Drug Coverage Parity Act, H.R. 1801/ S. 1879 Cancer Treatment Parity Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1801/S 1879 Cancer Drug Coverage Parity Act of 2013

Client expense: $37,725 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE